Based on the findings in the current study, we strongly suggest the investigate of the use of CXCR2 antagonists in the treatment of severe COVID-19, which may exert beneficial effects on a systemic level, including a reducing in NETosis-induced thrombosis. The gene discussed is CXCR2; the disease is deep vein thrombosis.